Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31591807 | 1.00 | PGR (0.38) | PGRMEN1KMT2ABACE1SLC6A2 | |
| SCHEMBL21629976 | 0.81 | AR (0.51) | ARCYP11B2 | |
| SCHEMBL31591806 | 0.81 | AR (0.51) | ARCYP11B2 | |
| SCHEMBL21630003 | 0.79 | AR (0.45) | PGRMEN1KMT2AARMGLL | |
| SCHEMBL31591784 | 0.79 | AR (0.45) | PGRMEN1KMT2AARMGLL | |
| SCHEMBL29374696 | 0.76 | ELANE (0.32) | PGRMGLL | |
| SCHEMBL21630040 | 0.73 | LMNA (0.36) | ARMGLL | |
| SCHEMBL31591921 | 0.73 | LMNA (0.36) | ARMGLL | |
| SCHEMBL21629966 | 0.72 | MGLL (0.34) | PGRMEN1KMT2AARMGLL | |
| SCHEMBL31591791 | 0.72 | MGLL (0.34) | PGRMEN1KMT2AARMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3818052-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | Gilead Sciences, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| CN-112384505-A | Therapeutic heterocyclic compounds | 吉利德科学公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200031801-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031801-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031801-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | SDHA, SLC10A1, CYP11B2 | PGR 2187/4885MEN1 391/4885KMT2A 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.